Peanut Allergy Vaccine R&D Increases with Significant Investment to Better Understand Immune Signatures Critical to Modulating Immune Responses to Allergens
In the U.S., peanut allergy is present in 0.6% of the population. Among children in the Western world, rates are between 1.5% and 3% and have increased over time. This has led to increasing investment in Peanut Allergy Vaccine . In December 2020, researchers at University of South Australia and Sementis received an NHMRC Ideas Grant that will support the team to better understand the immune signatures critical to modulating immune responses to allergens. It seems that when looking for treatments, there are two that constantly come up: Peanut Allergy Vaccine and Vaximab. Both of these are FDA approved but there are many people who question the efficiency of using human samples in treating diseases. Human samples cannot work at full capacity due to the various levels of gluten they may contain. It is also important to note that Vaximab clinical trial has not yet begun. The main argument against the use of Peanut Allergy Vaccine is that it lacks a proof of efficacy....